Backed by Or­biMed and J&J to build pre­ci­sion bac­te­ria-killing tool, Bio­mX adds a slate of in­vestors in $32M Se­ries B

When it comes to tin­ker­ing with the mul­ti­tude of bac­te­ria re­sid­ing in our bod­ies for dis­ease treat­ment, an­tibi­otics has been the go-to for elim­i­nat­ing bad ones while the bur­geon­ing crop of mi­cro­bio­me biotechs aim to add “good” mi­crobes to the mix. But a Weiz­mann In­sti­tute spin­out work­ing out of the Kendall Square of Is­rael is chart­ing a path be­tween those two ap­proach­es with the clin­i­cal stop in sight.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.